LONDON, March 20, 2014 /PRNewswire/ --
The trading session on Wednesday, March
19, 2014 ended on a negative note as the S&P 500
finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at
4,307.60, down 0.59%; the Dow Jones Industrial Average finished the
session 0.70% lower at 16,222.17. The losses were broad based as
all the sectors ended the session in negative. The S&P 500
Health Care Sector Index finished the day at 686.44, down 0.37%,
while the same has advanced 1.72% in the previous three trading
sessions. Investor-Edge has initiated coverage on the following
equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx
Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and
Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB,
PDLI and CELG can be downloaded upon signing up at:
http://www.investor-edge.com/365-register
Shares in Arena Pharmaceuticals Inc. recorded a trading volume of
3.34 million shares, as compared with a three months average volume
of 5.81 million shares. The stock ended the day at $6.52, down 1.29% and at an intraday range of
$6.46 and $6.67. Arena Pharmaceuticals Inc. shares have
declined 2.91% in the last one month, while the same has gained
0.39% in the previous three trading sessions and 11.37% on YTD
basis. The company's stock is trading above its 200-day moving
average. Arena Pharmaceuticals Inc.'s 50-day moving average of
$6.74 is above the 200-day moving
average of $6.39. Furthermore, the
stock is trading at the Relative Strength Index (RSI) of 46.11.
Sign up today to read free research on ARNA at:
http://www.investor-edge.com/365-ARNA-20Mar2014.pdf
On Wednesday, shares in Hemispherx Biopharma Inc. edged 0.38% lower
to finish the day at $0.40. The stock
recorded a trading volume of 1.07 million shares as compared to a
three months average volume of 3.14 million shares. The stock
fluctuated between $0.39 and $0.41
during the session. Hemispherx Biopharma Inc.'s stocks have
advanced 1.20% in the previous three trading sessions, 1.90% in the
last one month, and 49.92% on YTD basis. The company's shares are
trading above its 200-day moving average. Hemispherx Biopharma
Inc.'s 50-day moving average of $0.40
is above the 200-day moving average of $0.28. Moreover, the stock is trading at the
Relative Strength Index (RSI) of 49.48. Sign up today to read free
research on HEB at:
http://www.investor-edge.com/365-HEB-20Mar2014.pdf
PDL BioPharma Inc.'s stock finished Wednesday's session at its
previous day's closing price of $8.61. A total of 4.38 million shares were
traded, which is above the three months average volume of 2.74
million. The company's shares oscillated between $8.46 and $8.70 during the trading session.
Shares of the company traded at a PE ratio of 4.98. PDL BioPharma
Inc.'s shares have gained 4.24% in the previous three trading
sessions, 0.94% in the last one month, and 2.01% on YTD basis. The
company's stock is trading above its 200-day moving average. PDL
BioPharma Inc.'s 50-day moving average of $8.62 is above the 200-day moving average of
$8.29. Furthermore, the stock is
trading at the Relative Strength Index (RSI) of 53.46. Sign up
today to read free research on PDLI at:
http://www.investor-edge.com/365-PDLI-20Mar2014.pdf
Shares in Celgene Corp. recorded a trading volume of 2.85 million
shares, as compared with a three months average volume of 3.22
million shares. The stock finished the day at $150.84, down 1.85% after trading between
$150.11 and $155.99. Shares of the company traded at a PE
ratio of 32.23. Celgene Corp.'s stocks have advanced 0.96% in the
previous three trading sessions, while the same has declined 7.46%
in the last one month and 10.73% on YTD basis. The company's stock
is trading above its 200-day moving average. Celgene Corp.'s 50-day
moving average of $160.49 is above
the 200-day moving average of $149.04. Additionally, shares of the company are
trading at the Relative Strength Index (RSI) of 42.27. Sign up
today to read free research on CELG at:
http://www.investor-edge.com/365-CELG-20Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge